Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05931471 · ClinicalTrials.gov registry record · NA
Yogurt and GI Health
A NA study of Gut Microbiome and Gut Health, sponsored by USDA, Western Human Nutrition Research Center.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT05931471: Completed NA study of Gut Microbiome and Gut Health, sponsored by USDA, Western Human Nutrition Research Center.
NCT05931471 is a NA study of Gut Microbiome and Gut Health that has completed, run by USDA, Western Human Nutrition Research Center. The registered enrollment target is 32 participants, below the 266-participant average among 22 other Gut Microbiome trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05931471, a NA study of Gut Microbiome and Gut Health, has completed, sponsored by USDA, Western Human Nutrition Research Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to assess mucosal immune function responses in the gastrointestinal (GI) tract to twice-daily yogurt consumption. Previous research has shown that dairy yogurt intake can benefit gastrointestinal health. The current study will determine whether a dietary intervention with dairy yogurt will improve mucosal immunity and the gut microbiome.
Primary Outcome
Fecal secretory immunoglobulin A (sIgA) will be extracted then measured in duplicate by enzyme-linked immunosorbent assay (ELISA)
Conditions Studied
Interventions
- OTHER Yogurt Intervention
Study Locations (1)
California
- USDA Western Human Nutrition Research Center - Davis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-09-19 |
| Est. Completion | 2024-06-21 |
| Phase | NA |
What the finished NCT05931471 record still lists
NCT05931471 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 266-participant average among 22 other Gut Microbiome trials with a reported enrollment target (88% lower).
The record links to 4 conditions, with Gut Microbiome appearing as the primary indexed condition, and to 1 intervention - of which Yogurt Intervention is the first listed.
NCT05931471 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05931471 about?
NCT05931471 is a clinical study titled "Yogurt and GI Health". The purpose of this research is to assess mucosal immune function responses in the gastrointestinal (GI) tract to twice-daily yogurt consumption. Previous research has shown that dairy yogurt intake can benefit gastrointestinal health. The current study will determine whether a dietary intervention ...
What is the current status of trial NCT05931471?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2023-09-19. Estimated completion is 2024-06-21.
What conditions does trial NCT05931471 study?
This clinical trial studies the following conditions: Gut Microbiome, Gut Health, Yogurt Intake, Gastrointestinal Immune Function.
What interventions are being tested in trial NCT05931471?
The interventions under investigation include: Yogurt Intervention (OTHER).
Who is sponsoring clinical trial NCT05931471?
This trial is sponsored by USDA, Western Human Nutrition Research Center, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05931471 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gut Microbiome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05931471's enrollment target sits among peer trials
32 18th of 22 higher than 5 of 22 other Gut Microbiome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gut Microbiome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Flourish: Exploring the Early Infant Gut Microbiome
RECRUITING · NA
-
The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study
RECRUITING · NA
-
Enhanced Nutritional Optimization in LVAD Trial
RECRUITING · NA
-
Feasibility and Potential Efficacy of Herbs and Spices for Improving Dietary Quality in College Students: A Pilot Study
RECRUITING · NA
-
How a Single Workout Affects Gut Bugs in Women With Different Fitness Levels and Body Types
RECRUITING · NA
-
The Effect Cranberry-Based Products on the Female Microbiome
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI